Associations of Medications With Lower Odds of Typical COVID-19 Symptoms : Cross-Sectional Symptom Surveillance Study
©Dietmar Urbach, Friedemann Awiszus, Sven Leiß, Tamsin Venton, Alexander Vincent De Specht, Christian Apfelbacher. Originally published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 14.12.2020..
BACKGROUND: As the COVID-19 pandemic continues to spread across the globe, the search for an effective medication to treat the symptoms of COVID-19 continues as well. It would be desirable to identify a medication that is already in use for another condition and whose side effect profile and safety data are already known and approved.
OBJECTIVE: The objective of this study was to evaluate the effect of different medications on typical COVID-19 symptoms by using data from an online surveillance survey.
METHODS: Between early April and late-July 2020, a total of 3654 individuals in Lower Saxony, Germany, participated in an online symptom-tracking survey conducted through the app covid-nein-danke.de. The questionnaire comprised items on typical COVID-19 symptoms, age range, gender, employment in patient-facing healthcare, housing status, postal code, previous illnesses, permanent medication, vaccination status, results of reverse transcription polymerase chain reaction (RT-PCR) and antibody tests for COVID-19 diagnosis, and consequent COVID-19 treatment if applicable. Odds ratio estimates with corresponding 95% CIs were computed for each medication and symptom by using logistic regression models.
RESULTS: Data analysis suggested a statistically significant inverse relationship between typical COVID-19 symptoms self-reported by the participants and self-reported statin therapy and, to a lesser extent, antihypertensive therapy. When COVID-19 diagnosis was based on restrictive symptom criteria (ie, presence of 4 out of 7 symptoms) or a positive RT-PCR test, a statistically significant association was found solely for statins (odds ratio 0.28, 95% CI 0.1-0.78).
CONCLUSIONS: Individuals taking statin medication are more likely to have asymptomatic COVID-19, in which case they may be at an increased risk of transmitting the disease unknowingly. We suggest that the results of this study be incorporated into symptoms-based surveillance and decision-making protocols in regard to COVID-19 management. Whether statin therapy has a beneficial effect in combating COVID-19 cannot be deduced based on our findings and should be investigated by further study.
TRIAL REGISTRATION: German Clinical Trials Register DRKS00022185; https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022185; World Health Organization International Clinical Trials Registry Platform U1111-1252-6946.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
JMIR public health and surveillance - 6(2020), 4 vom: 14. Dez., Seite e22521 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Urbach, Dietmar [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.01.2021 Date Revised 07.12.2022 published: Electronic DRKS: DRKS00022185 Citation Status MEDLINE |
|---|
| doi: |
10.2196/22521 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317652567 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317652567 | ||
| 003 | DE-627 | ||
| 005 | 20231225163719.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2196/22521 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1058.xml |
| 035 | |a (DE-627)NLM317652567 | ||
| 035 | |a (NLM)33197879 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Urbach, Dietmar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Associations of Medications With Lower Odds of Typical COVID-19 Symptoms |b Cross-Sectional Symptom Surveillance Study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a DRKS: DRKS00022185 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©Dietmar Urbach, Friedemann Awiszus, Sven Leiß, Tamsin Venton, Alexander Vincent De Specht, Christian Apfelbacher. Originally published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 14.12.2020. | ||
| 520 | |a BACKGROUND: As the COVID-19 pandemic continues to spread across the globe, the search for an effective medication to treat the symptoms of COVID-19 continues as well. It would be desirable to identify a medication that is already in use for another condition and whose side effect profile and safety data are already known and approved | ||
| 520 | |a OBJECTIVE: The objective of this study was to evaluate the effect of different medications on typical COVID-19 symptoms by using data from an online surveillance survey | ||
| 520 | |a METHODS: Between early April and late-July 2020, a total of 3654 individuals in Lower Saxony, Germany, participated in an online symptom-tracking survey conducted through the app covid-nein-danke.de. The questionnaire comprised items on typical COVID-19 symptoms, age range, gender, employment in patient-facing healthcare, housing status, postal code, previous illnesses, permanent medication, vaccination status, results of reverse transcription polymerase chain reaction (RT-PCR) and antibody tests for COVID-19 diagnosis, and consequent COVID-19 treatment if applicable. Odds ratio estimates with corresponding 95% CIs were computed for each medication and symptom by using logistic regression models | ||
| 520 | |a RESULTS: Data analysis suggested a statistically significant inverse relationship between typical COVID-19 symptoms self-reported by the participants and self-reported statin therapy and, to a lesser extent, antihypertensive therapy. When COVID-19 diagnosis was based on restrictive symptom criteria (ie, presence of 4 out of 7 symptoms) or a positive RT-PCR test, a statistically significant association was found solely for statins (odds ratio 0.28, 95% CI 0.1-0.78) | ||
| 520 | |a CONCLUSIONS: Individuals taking statin medication are more likely to have asymptomatic COVID-19, in which case they may be at an increased risk of transmitting the disease unknowingly. We suggest that the results of this study be incorporated into symptoms-based surveillance and decision-making protocols in regard to COVID-19 management. Whether statin therapy has a beneficial effect in combating COVID-19 cannot be deduced based on our findings and should be investigated by further study | ||
| 520 | |a TRIAL REGISTRATION: German Clinical Trials Register DRKS00022185; https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022185; World Health Organization International Clinical Trials Registry Platform U1111-1252-6946 | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antihypertensives | |
| 650 | 4 | |a hydroxymethyl-glutaryl-coenzyme A reductase inhibitors | |
| 650 | 4 | |a online survey | |
| 650 | 4 | |a statins | |
| 650 | 4 | |a surveillance | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 700 | 1 | |a Awiszus, Friedemann |e verfasserin |4 aut | |
| 700 | 1 | |a Leiß, Sven |e verfasserin |4 aut | |
| 700 | 1 | |a Venton, Tamsin |e verfasserin |4 aut | |
| 700 | 1 | |a Specht, Alexander Vincent De |e verfasserin |4 aut | |
| 700 | 1 | |a Apfelbacher, Christian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JMIR public health and surveillance |d 2015 |g 6(2020), 4 vom: 14. Dez., Seite e22521 |w (DE-627)NLM257939679 |x 2369-2960 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2020 |g number:4 |g day:14 |g month:12 |g pages:e22521 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2196/22521 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2020 |e 4 |b 14 |c 12 |h e22521 | ||